Drug Response Testing and Repurposing Using Glioblastoma Organoid
Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
Chungnam National University Hospital
150 participants
Aug 18, 2021
OBSERVATIONAL
Conditions
Summary
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Eligibility
Inclusion Criteria3
- primary or recurrent glioblastoma
- patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
- sufficient tumor sample is available for organoid culture
Exclusion Criteria3
- patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery
- failed to obtain MRI scan after CCRT
- patients refusal
Interventions
The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis. The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06782984